Evofem Biosciences, Inc. (EVFM) financial statements (2022 and earlier)

Company profile

Business Address 12400 HIGH BLUFF DRIVE
SAN DIEGO, CA 92130
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments7,73248,89215,5711,3303,41711,47837,749
Cash and cash equivalents7,73248,89215,5711,3303,41711,47837,749
Restricted cash and investments5,05622,559304431   
Receivables6,4491,067     
Inventory, net of allowances, customer advances and progress billings7,6747,162     
Inventory7,6747,162     
Other undisclosed current assets3,22918,05010,5467176081,0301,977
Total current assets:30,14097,73026,4212,4784,02512,50739,726
Noncurrent Assets
Operating lease, right-of-use asset5,3956,856 
Property, plant and equipment5,7744,334394593 109186
Restricted cash and investments    93  
Other noncurrent assets1,2031,0481,320939   
Other undisclosed noncurrent assets  160  200200
Total noncurrent assets:12,37212,2381,8741,53293309386
TOTAL ASSETS:42,512109,96828,2954,0104,11912,81740,112
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities23,33921,63112,46223,3191,4125434,920
Accounts payable10,31610,6416,0088,8825665044,017
Accrued liabilities8,3704,4762,78411,51384639903
Employee-related liabilities4,6536,5143,6702,924   
Debt 52,409 4,010  2,756
Derivative instruments and hedges, liabilities202      
Other liabilities2,864953     
Other undisclosed current liabilities111,2582,290197  3591,423
Total current liabilities:137,66377,28312,65927,3291,4129029,100
Noncurrent Liabilities
Long-term debt and lease obligation4,42431,338    7,205
Long-term debt, excluding current maturities 25,308    7,205
Operating lease, liability4,4246,030 
Liabilities, other than long-term debt   37   
Deferred revenue and credits37   
Other undisclosed noncurrent liabilities(4,424)(6,030)     
Total noncurrent liabilities:4,42431,338 37  7,205
Total liabilities:142,087108,62112,65927,3661,41290216,305
Stockholders' equity
Stockholders' equity attributable to parent(104,315)1,34715,636(23,356)2,70711,91523,807
Common stock16853011
Additional paid in capital751,260656,827528,810409,787138,550137,763136,638
Accumulated other comprehensive income5,089      
Accumulated deficit(860,680)(655,488)(513,179)(433,146)(135,844)(125,850)(112,832)
Other undisclosed stockholders' equity4,740      
Total stockholders' equity:(99,575)1,34715,636(23,356)2,70711,91523,807
TOTAL LIABILITIES AND EQUITY:42,512109,96828,2954,0104,11912,81740,112

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues8,244446     
Cost of revenue
(Cost of Goods and Services Sold)
(4,055)(468)     
Gross profit:4,189(22)     
Operating expenses(170,990) (52,742)(77,642)(10,045)(12,042)(42,049)
Other undisclosed operating loss (103,602)     
Operating loss:(166,801)(103,624)(52,742)(77,642)(10,045)(12,042)(42,049)
Nonoperating income (expense)(38,374)(38,681)(27,287)(48,068)515926
Investment income, nonoperating15169458127515926
Interest and debt expense(2,665)(2,061)   (1,036)(1,134)
Other undisclosed income from continuing operations before equity method investments, income taxes 2,061     
Loss from continuing operations before equity method investments, income taxes:(207,840)(142,305)(80,029)(125,710)(9,993)(13,019)(43,157)
Other undisclosed income from continuing operations before income taxes2,665      
Loss from continuing operations before income taxes:(205,175)(142,305)(80,029)(125,710)(9,993)(13,019)(43,157)
Income tax expense(17)(4)(4)(2)   
Net loss attributable to parent:(205,192)(142,309)(80,033)(125,712)(9,993)(13,019)(43,157)
Preferred stock dividends and other adjustments   (66)   
Other undisclosed net loss available to common stockholders, basic(1,047)      
Net loss available to common stockholders, diluted:(206,239)(142,309)(80,033)(125,778)(9,993)(13,019)(43,157)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net loss:(205,192)(142,309)(80,033)(125,712)(9,993)(13,019)(43,157)
Comprehensive loss:(205,192)(142,309)(80,033)(125,712)(9,993)(13,019)(43,157)
Other undisclosed comprehensive income, net of tax, attributable to parent5,089      
Comprehensive loss, net of tax, attributable to parent:(200,103)(142,309)(80,033)(125,712)(9,993)(13,019)(43,157)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: